Pharmagreen Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020
Net Income	-0.23	-1	-0.57	-0.88	-4.53	-2.44
Other Amortization	-	-	0.07	0.02	0.09	0.33
Asset Writedown & Restructuring Costs	-	-	-	-	-	0.43
Stock-Based Compensation	-	-	0.08	0.46	0.63	0.01
Other Operating Activities	-0.07	0.72	0	-0.27	3.7	1.19
Change in Accounts Receivable	0	0	-0	-0	0	0.01
Change in Inventory	0	0	-0.01	-	-	-
Change in Accounts Payable	0.15	0.13	0.14	0.07	0.15	-0.09
Change in Other Net Operating Assets	0.11	0.12	0.22	0.18	-0.24	-0.06
Operating Cash Flow	-0.03	-0.03	-0.07	-0.43	-0.21	-0.61
Short-Term Debt Issued	-	-	-	-	0.03	0.1
Long-Term Debt Issued	-	0.03	0.08	0.14	-	0.6
Total Debt Issued	0.04	0.03	0.08	0.14	0.03	0.7
Short-Term Debt Repaid	-	-	-	-	-0.04	-0.14
Long-Term Debt Repaid	-	-0	-	-0.01	-	-0.03
Total Debt Repaid	-0	-0	-	-0.01	-0.04	-0.17
Net Debt Issued (Repaid)	0.04	0.03	0.08	0.13	-0.01	0.53
Issuance of Common Stock	-	-	-	0.19	0.27	0.04
Other Financing Activities	-	-	-	-	-	-0.01
Financing Cash Flow	0.04	0.03	0.08	0.31	0.26	0.56
Foreign Exchange Rate Adjustments	-0.01	-0	-0.02	0.1	-0.04	-0.01
Net Cash Flow	0	-0	-0.01	-0.02	0.01	-0.05
Free Cash Flow	-0.03	-0.03	-0.07	-0.43	-0.21	-0.61
Free Cash Flow Margin	-1098.63%	-823.64%	-2462.91%	-	-	-
Free Cash Flow Per Share	-	-	-	-0.00	-0.00	-0.01
Cash Interest Paid	-	-	-	-	-	0
Levered Free Cash Flow	-0.16	0.79	0.18	-0.17	-1.02	0.59
Unlevered Free Cash Flow	-0.14	0.81	0.19	-0.16	-0.63	0.68
Change in Working Capital	0.26	0.25	0.35	0.24	-0.09	-0.13

Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.